Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.

Dimopoulos, Meletios A, Richardson, Paul G, Bahlis, Nizar J, Grosicki, Sebastian, Cavo, Michele, Beksaç, Meral, Legieć, Wojciech, Liberati, Anna M, Goldschmidt, Hartmut, Belch, Andrew, Magen, Hila, Larocca, Alessandra, Laubach, Jacob P, Petrucci, Maria T, Reece, Donna, White, Darrell, Mateos, María-Victoria, Špička, Ivan, Lazaroiu, Mihaela, Berdeja, Jesús, Kaufman, Jonathan L, Jou, Ying-Ming, Ganetsky, Alex, Popa McKiver, Mihaela, Lonial, Sagar, Weisel, Katja

Open source

DOI: 10.48350/174434
Published: 2022
Container: Not recorded
Publisher: University of Bern
Open access: no

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
supportingPublication license: A publication license was supplied: http://purl.org/coar/access_right/c_16ec. Presence improves reuse transparency, not research validity. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.48350/174434,
  title = {Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.},
  author = {Dimopoulos, Meletios A and Richardson, Paul G and Bahlis, Nizar J and Grosicki, Sebastian and Cavo, Michele and Beksaç, Meral and Legieć, Wojciech and Liberati, Anna M and Goldschmidt, Hartmut and Belch, Andrew and Magen, Hila and Larocca, Alessandra and Laubach, Jacob P and Petrucci, Maria T and Reece, Donna and White, Darrell and Mateos, María-Victoria and Špička, Ivan and Lazaroiu, Mihaela and Berdeja, Jesús and Kaufman, Jonathan L and Jou, Ying-Ming and Ganetsky, Alex and Popa McKiver, Mihaela and Lonial, Sagar and Weisel, Katja},
  year = {2022},
  doi = {10.48350/174434},
  url = {https://doi.org/10.48350/174434}
}

RIS

TY  - JOUR
TI  - Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
AU  - Dimopoulos, Meletios A
AU  - Richardson, Paul G
AU  - Bahlis, Nizar J
AU  - Grosicki, Sebastian
AU  - Cavo, Michele
AU  - Beksaç, Meral
AU  - Legieć, Wojciech
AU  - Liberati, Anna M
AU  - Goldschmidt, Hartmut
AU  - Belch, Andrew
AU  - Magen, Hila
AU  - Larocca, Alessandra
AU  - Laubach, Jacob P
AU  - Petrucci, Maria T
AU  - Reece, Donna
AU  - White, Darrell
AU  - Mateos, María-Victoria
AU  - Špička, Ivan
AU  - Lazaroiu, Mihaela
AU  - Berdeja, Jesús
AU  - Kaufman, Jonathan L
AU  - Jou, Ying-Ming
AU  - Ganetsky, Alex
AU  - Popa McKiver, Mihaela
AU  - Lonial, Sagar
AU  - Weisel, Katja
PY  - 2022
DO  - 10.48350/174434
UR  - https://doi.org/10.48350/174434
ER  -

APA

A, D. M., G, R. P., J, B. N., Sebastian, G., Michele, C., Meral, B., Wojciech, L., M, L. A., Hartmut, G., Andrew, B., Hila, M., Alessandra, L., P, L. J., T, P. M., Donna, R., Darrell, W., María-Victoria, M., Ivan, Š., Mihaela, L., Jesús, B., L, K. J., Ying-Ming, J., Alex, G., Mihaela, P. M., Sagar, L., & Katja, W. (2022). Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.. https://doi.org/10.48350/174434

Source records

datacite · retrieved 2026-09-27T00:59:55.789Z